| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
"Phase 3 topline data readout" example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders | ||
"Phase 3 topline data readout" example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders | ||
"Phase 3 topline data readout" example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders |
Recent Updates
Recently added Catalysts
LB Pharmaceuticals Inc$32.95
-0.79 (-2.34%)
D 33Pipeline Score Overvalued Pharma · Clinical
Market Cap
806.39 M
EPS
-1.49
P/E Ratio
-
Value Trade
5.52 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
14.64 M
Operating CF
-23.29 M
Total Assets
393.48 M
Total Liabilities
14.79 M
Equity
378.69 M
D/E Ratio
12,345
-8.82 %
Week
-11.9 %
1 Month
16.44 %
3 Month
75.75 %
6 Month
48 %
5 Year
48 %
All Time
Cash Data
Cash Position
365.64 M
Monthly Burn
7.76 M
Runway
45.4 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
186.56 K
52 Week Range
13.36 - 33.47
% held by Insiders
27.59 %
% held by Institutions
87.22 %
Enterprise Value
444.22 M
Total Shares
28.66 M
Short %
20.73 %
Float Shares
23.84 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for LB Pharmaceuticals Inc
32Total events
7Upcoming
5Tier-1 (high impact)
2025 – 2029Coverage
Upcoming catalysts 7
Event history 25
Jun 30, 2026
◆Management ChangeCorporate
Appointment of Christopher Zergebel as Senior Vice President, Clinical Operations
Jun 16, 2026
◆Oral PresentationPresentation
H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference presentation
Jun 4, 2026
May 13, 2026
▲Trial InitiationLB-102Trial
Initiated Phase 2 ILLUMINATE-1 trial of LB-102 in bipolar depression
bipolar depressionsource ↗
May 13, 2026
▲PublicationLB-102Presentation
Published Phase 2 NOVA-1 results in JAMA Psychiatry
schizophreniasource ↗
Apr 22, 2026
▲PublicationLB-102Presentation
Publication of Phase 2 NOVA-1 trial results in JAMA Psychiatry
schizophreniasource ↗
Apr 16, 2026
◆Oral PresentationPresentation
Presentation at 25th Annual Needham Virtual Healthcare Conference
Mar 27, 2026
▲Oral PresentationLB-102Presentation
Oral presentation of post hoc analysis of LB-102 effect on cognitive performance at SIRS 2026
schizophreniasource ↗
Mar 27, 2026
▲Trial InitiationLB-102Trial
Initiation of Phase 2 ILLUMINATE-1 trial of LB-102 for bipolar depression
bipolar depressionsource ↗
Mar 25, 2026
▲Trial InitiationLB-102Trial
Initiation of Phase 2 ILLUMINATE-1 trial for LB-102 in bipolar depression
bipolar depressionsource ↗
Drug Pipeline Intelligence
D33
Pipeline Score $128M
Pipeline ValueOvervalued
Valuation Signal1
Drugs Scored0.2x
rNPV / MCap Top 42%
Micro Cap (rank 529 of 911)
Percentile RankLB Pharmaceuticals Inc faces pipeline headwinds (33/100), with $321M risk-adjusted pipeline value, led by LB-102 in Schizophrenia (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LB-102 Small molecule | Schizophrenia | Phase 3 | NCT04588129 | 49% | $321M | COMPLETED | 1,795 | - | - | Nov 15, 2021 | LOW_RISK | May 4, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
LB-102 | acute schizophrenia | Phase 2 | 2026-05-13 | statistically significant benefit versus placebo at all doses studied, rapid onset of effect at week 1, sustained benefit through the endpoint of the trial Read More | LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update Read More | |
LB-102 | acute schizophrenia | Phase 2 | 2026-05-13 | statistically significant benefit versus placebo at all doses studied, rapid onset of effect at week 1, sustained benefit through the endpoint of the trial Read More | LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update Read More | |
LB-102 | acute schizophrenia | Phase 2 | 2026-05-13 | statistically significant benefit versus placebo at all doses studied, rapid onset of effect at week 1, sustained benefit through the endpoint of the trial Read More | LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LBRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LBRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LBRXLB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations
LB Pharmaceuticals has appointed Christopher Zergebel as Senior Vice President of Clinical Operations. With over 25 years of experience, Zergebel will lead efforts in executing multiple clinical trials for LB-102, a candidate aimed at treating schizophrenia and bipolar depression. The company is optimistic about the potential of LB-102 to meet significant patient needs.
Read more →LBRXLB Pharmaceuticals to Participate in Upcoming June 2026 Investor Events
LB Pharmaceuticals Inc. will participate in two upcoming investor conferences in June 2026. The events include the Jefferies Global Healthcare Conference and the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The company aims to showcase its late-stage development of therapies for neuropsychiatric diseases, particularly its lead candidate, LB-102.
Read more →LBRXLB Pharmaceuticals to Participate in Upcoming June Investor Events
LB Pharmaceuticals Inc. has announced its participation in two upcoming investor conferences, the Jefferies Global Healthcare Conference on June 4, 2026, and the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on June 16, 2026. The company is focused on developing innovative therapies for schizophrenia and other neuropsychiatric diseases, with its lead candidate, LB-102, showing promise as a potential first-in-class treatment.
Read more →LBRXLB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
LB Pharmaceuticals reported its first quarter 2026 financial results, highlighting the initiation of two late-stage clinical trials for its lead product, LB-102, aimed at treating schizophrenia and bipolar depression. The company also announced a strong cash position expected to fund operations through multiple clinical milestones. Positive data from a prior Phase 2 trial has been published, supporting the drug's potential in neuropsychiatric disorders.
Read more →LBRXLB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
LB Pharmaceuticals announced the publication of positive results from the Phase 2 NOVA-1 trial of LB-102 in JAMA Psychiatry. The investigational drug demonstrated significant efficacy in treating acute schizophrenia and is advancing to a pivotal Phase 3 trial (NOVA-2). If successful, LB-102 could be the first benzamide approved for schizophrenia in the U.S.
Read more →LBRX▼ -7.4%on this news
LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference
LB Pharmaceuticals Inc. announced that CEO Heather Turner will present at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026. The company is focused on developing therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders. Their lead candidate, LB-102, aims to be a first-in-class treatment for these conditions.
Read more →LBRXLB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
LB Pharmaceuticals presented new data on LB-102 at the SIRS conference, highlighting its potential to improve cognitive performance in schizophrenia patients. The Phase 2 NOVA-1 trial showed that LB-102 significantly enhances cognition independently of its effects on overall schizophrenia symptoms. The company is now evaluating cognitive performance as a secondary endpoint in its upcoming Phase 3 trial.
Read more →LBRXLB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
LB Pharmaceuticals presented new findings from the Phase 2 NOVA-1 trial of LB-102 at the SIRS Congress, highlighting its potential to improve cognitive performance in schizophrenia patients. The analysis showed that cognitive benefits were primarily a direct effect of LB-102, independent of overall symptom improvement. The company plans to evaluate cognitive performance as a secondary endpoint in its upcoming Phase 3 trial.
Read more →LBRXLB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
LB Pharmaceuticals reported positive results from its Phase 2 trial of LB-102 for schizophrenia and has advanced the drug into late-stage development with a pivotal Phase 3 trial. The company also plans to initiate a Phase 2 trial for major depressive disorder in 2027. With a strong financial position, LB Pharmaceuticals aims to expand its pipeline in neuropsychiatric disorders.
Read more →LBRXLB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia
LB Pharmaceuticals has initiated its pivotal Phase 3 trial, NOVA-2, for LB-102, targeting schizophrenia. The trial aims to enroll around 460 patients and evaluate the drug's efficacy and safety, with results expected in the second half of 2027. If successful, LB-102 could become the first benzamide approved for schizophrenia in the U.S., addressing significant unmet needs in treatment.
Read more →LBRXLB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
LB Pharmaceuticals has appointed Dr. Robert Lenz to its Board of Directors, enhancing its leadership with his extensive experience in neuroscience R&D. The company is progressing its lead product candidate, LB-102, into late-stage clinical development for various neuropsychiatric disorders. Dr. Lenz expressed enthusiasm about contributing to the company's growth and advancing LB-102's potential therapeutic benefits.
Read more →LBRXLB Pharmaceuticals to Participate in Upcoming March 2026 Investor Events
LB Pharmaceuticals Inc. announced its participation in two upcoming investor conferences in March 2026. The company is focused on developing innovative therapies for schizophrenia and other neuropsychiatric disorders. Their lead candidate, LB-102, aims to be the first benzamide antipsychotic approved in the U.S. for these conditions.
Read more →LBRXLB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - February 10, 2026
LB Pharmaceuticals announced the grant of an equity award to Dr. Minako Pazdera, the new General Counsel, under Nasdaq Listing Rule 5635(c)(4). The award consists of options to purchase 140,000 shares, vesting over four years. The company is also advancing its lead candidate, LB-102, with ongoing Phase 2 trials and plans for a Phase 3 trial for schizophrenia.
Read more →LBRX▲ +12.7%on this news
LB Pharmaceuticals Announces $100.0 Million Private Placement
LB Pharmaceuticals has announced a $100 million private placement to fund its Phase 2 trial for LB-102, aimed at treating major depressive disorder. The company will sell over 3.3 million shares and pre-funded warrants to institutional investors. The placement is set to close on February 6, 2026, pending customary conditions.
Read more →LBRXLB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program
LB Pharmaceuticals has initiated a Phase 2 trial for LB-102 in bipolar depression, following positive results in schizophrenia. The trial aims to evaluate the drug's efficacy and safety, with results expected in early 2028. The company believes LB-102 can address significant unmet needs in mood disorders, leveraging its favorable pharmacologic profile.
Read more →LBRXLB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel
LB Pharmaceuticals has appointed Dr. Minako Pazdera as General Counsel, bringing over 25 years of experience in corporate governance and intellectual property. Dr. Pazdera's expertise is expected to enhance the company's strategic initiatives as it advances LB-102, a promising treatment for schizophrenia and bipolar depression, into further clinical trials. The company aims to address unmet needs in neuropsychiatric disorders.
Read more →LBRXLB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
LB Pharmaceuticals announced equity awards to new executives Ellen Rose and Lindsay Beaupre as part of their inducement to join the company. The awards were granted under Nasdaq Listing Rule 5635(c)(4) and include options to purchase shares at a set price. Additionally, LB-102, their lead product, is advancing into Phase 3 trials for schizophrenia after positive Phase 2 results.
Read more →LBRX▼ -5.3%on this news
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - December 10, 2025
LB Pharmaceuticals announced an inducement equity grant to Kaya Pai Panandiker, its new Chief Commercial Officer, under Nasdaq Listing Rule 5635(c)(4). The grant includes options to purchase 195,000 shares at $21.36, vesting over four years. Additionally, LB-102 is progressing to Phase 3 trials following positive Phase 2 results in schizophrenia treatment.
Read more →LBRX▼ -5.6%on this news
LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer
LB Pharmaceuticals has appointed Kaya Pai Panandiker as its new Chief Commercial Officer. With over 20 years of experience in the biopharmaceutical industry, she is expected to leverage her expertise in neuroscience commercialization to advance the company's lead product, LB-102, toward registration and commercialization. LB-102, currently in Phase 2 trials with promising results for schizophrenia and bipolar depression, represents a significant potential advancement in treating neuropsychiatric disorders. However, the company acknowledges the challenges ahead, including securing funding and navigating regulatory pathways.
Read more →LBRXLB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates
LB Pharmaceuticals reported its financial results for Q3 2025, showing reduced research and administrative costs, contributing to a net loss of $3.6 million, down from $14.2 million in Q3 2024. The CEO highlighted the positive results of a recent Phase 2 trial for LB-102, which is set to advance to a Phase 3 trial for acute schizophrenia. The company has a substantial cash reserve of approximately $314.5 million post-IPO, supporting operations expected to last through Q2 2028. Additionally, LB-102 may expand indications into bipolar depression and other neuropsychiatric disorders.
Read more →Competitive Position
How LBRX ranks across every disease it competes inCompetitive Position is a premium feature
See how LBRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial